Balaxi Pharmaceuticals Q1 Results, Total Income at ₹6,377.36 Lakhs with Net Profit at ₹648.04 Lakhs

Balaxi Pharmaceuticals Q1 Results: Balaxi Pharmaceuticals reported their financial results for the first quarter of the 2024-2025 fiscal year on August 2, 2024. The company achieved a total income of ₹6,377.36 lakhs, which represents a 9.83% increase compared to the ₹5,804.71 lakhs recorded in the previous quarter.

This growth in income is mainly attributed to increased sales and effective operational strategies. Despite this positive trend in revenue, the company's total expenses were ₹5,639.87 lakhs, showing a slight decrease of 2.16% from ₹5,764.28 lakhs in the previous quarter.

Net profit for the quarter was ₹648.04 lakhs, up from ₹1,093.38 lakhs in the prior quarter, reflecting a decrease of 40.65%. This drop in net profit is primarily due to higher operating costs and an absence of exceptional items.

The company maintained a strong paid-up equity share capital of ₹1,104.15 lakhs, which is a 1.32% increase from ₹1,089.78 lakhs in the previous quarter. Balaxi Pharmaceuticals' results indicate solid performance and ongoing investment in its operations despite the reduction in profit.

For More Q1 results check our Twitter Page

Balaxi Pharmaceuticals Q1 Results 2024 - 2025

Balaxi Pharmaceuticals has released its financial results for the first quarter of the 2024-2025 fiscal year. The company reported an increase in total income and a slight decrease in expenses but experienced a drop in net profit compared to the previous quarter. Below is a summary of their Q1 results:

Source: Click Here

Balaxi Pharmaceuticals Current Market Overview

Balaxi Pharmaceuticals is currently trading at ₹109, with a market capitalization of ₹604 crore. The stock has fluctuated between a high of ₹151 and a low of ₹80 recently. It has a price-to-earnings (P/E) ratio of 16.0 and a book value of ₹36.3 per share. The company does not pay a dividend and has a return on capital employed (ROCE) of 21.4%, showing efficient use of capital.

However, its return on equity (ROE) is -26.9%, indicating a loss for shareholders. The shares have a face value of ₹2.00.

Quarterly Results

Here are the quarterly results for Balaxi Pharmaceuticals for the periods ending December 2023, March 2024, and June 2024:

About Balaxi Pharmaceuticals

Balaxi Pharmaceuticals is a pharmaceutical company that focuses on producing and supplying both branded and generic medicines. They have a diverse range of products, including tablets, injectables, liquids, and capsules. The company sources its medicines from WHO-GMP-certified manufacturers located in India, China, and Portugal.

Balaxi Pharmaceuticals is dedicated to maintaining high-quality standards in its products and aims to provide effective healthcare solutions globally. Their extensive product portfolio and commitment to quality make them a significant player in the pharmaceutical industry.

Visit our website for more Q1 results.